Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
Authors
Trumper, MRoss, P J
Cunningham, David
Norman, A
Hawkins, Robert E
Seymour, M T
Harper, P
Iveson, T
Nicolson, M
Hickish, T
Affiliation
Section of Medicine, Gastrointestinal Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.Issue Date
2006-05
Metadata
Show full item recordAbstract
The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients. 1080 patients were enrolled into three randomised controlled trials assessing fluorouracil-based combination chemotherapy. Patients received either a platinum-containing regimen (ECF, MCF), PVI 5-FU (protracted venous infusion of 5-fluorouracil)+/-mitomycin C (MMC), or FAMTX. Of the 1080 patients randomised, 257 (23.8%) were aged > or =70 years. There were no significant differences in the incidence of grades 3/4 toxicity between the two cohorts. Objective and symptomatic response rates, failure-free and overall survival were not significantly different. In a multivariate analysis, independent prognostic factors for survival were performance status and locally advanced disease, not age. Patients > or =70 years with OGC obtained similar benefits from palliative chemotherapy with respect to symptomatic response, tumour regression and survival, without increased toxicities.Citation
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. 2006, 42 (7):827-34 Eur. J. CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2005.08.044PubMed ID
16466913Type
ArticleLanguage
enISSN
0959-8049ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2005.08.044
Scopus Count
Collections
Related articles
- A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
- Authors: Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M
- Issue date: 2002 Oct
- Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
- Authors: Kelleher M, Tebbutt NC, Cunningham D, Andreyev J, Allen M, Hill M, Norman A
- Issue date: 2003 May
- Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
- Authors: Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A
- Issue date: 2002 Apr 15
- Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
- Authors: Okines AFC, Norman AR, McCloud P, Kang YK, Cunningham D
- Issue date: 2009 Sep
- Chemotherapy of oesophago-gastric cancer.
- Authors: Ross PJ, Rao S, Cunningham D
- Issue date: 1998